/

Empresas

Io

No verificado

Io Therapeutics, Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaMedicina Salud Bienestar

4 Comunicados de prensa

Ver todos los comunicados de prensa

18/09/2024

Biotecnología

Medicina Salud Bienestar

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

Fuente

Io Therapeutics, Inc.

Editor

1,00

0

16/07/2024

Biotecnología

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)

Fuente

Io Therapeutics, Inc.

Editor

1,00

0

09/07/2024

Biotecnología

Medicina Salud Bienestar

Anuncios breves

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

Fuente

Io Therapeutics, Inc.

Editor

1,00

0

08/07/2024

Biotecnología

Medicina Salud Bienestar

Anuncios breves

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound

Fuente

Io Therapeutics, Inc.

Editor

1,00

0

Seguidores

0

Compatibilidad

0